Use of LHRH antagonists for intermittent treatments

A method for treating a prostate cancer, the method comprising:

• administering at least one LHRH antagonist to a subject in need thereof in an amount sufficient to treat the prostate cancer and in a dose which does not cause a chemical or hormonal castration, wherein the at least one LHRH antagonist is a tetrahydrocarbazole derivative with the formula
• wherein V and W are each independently O, S, S+—O−, or geminally linked H2;
• R1 is O, S, or S+—O−;
• R2 is an optionally substituted cycloalkyl, cycloalkylakyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, or —NHX1, wherein X1 is an optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, and wherein R2 or X1 is optionally substituted with —F, —Cl, —Br, —I, —CF3, or —OCF3;
• R4m is an optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, and wherein R4m is optionally substituted with —F, —Cl, —Br, —I, —CF3, or —OCF3;
• R8 is an optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, and wherein R8 is optionally substituted with —F, —Cl, —Br, —I, —CF3, or —OCF3;
• R10 is an optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or —C(O)X1004, wherein X1004 is an optionally substituted cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, and wherein R10 or X1004 is optionally substituted with —F, —Cl, —Br, —I, —CF3, or —OCF3;
• and
• R17, R18, R10, and R20 are each independently —H, —F, —Cl, —Br, —I, —CF3, or —OCF3.